Transthyretin Amyloid Cardiomyopathy (ATTR-CM): An Evolution in Management

Pre-registration for:
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): An Evolution in Management

Saturday, November 7, 2026

Dinner & Registration: 5:30 pm to 6:00 pm CT
Symposium: 6:00 pm to 7 pm CT

McCormick Place Convention Center
2301 S. Dr. Martin Luther King Jr. Drive
Chicago, Illinois

Register using the form provided below. Click HERE for additional meeting details.
 
Register using the form provided below. Click HERE for additional meeting details.
+ Add a Registration
Security Check *
* Required fields.
Symposium Poster

Program Overview:

Transthyretin amyloidosis (ATTR) is a progressive, multisystemic, life-threatening disease characterized by deposits of amyloid fibrils in the peripheral nerves, heart, and other tissues and organs, resulting in polyneuropathy (PN), cardiomyopathy (CM), or a mix of both neurologic and cardiac manifestations. ATTR amyloidosis may be caused by one of over 130 pathogenic mutations that destabilize the TTR protein (hereditary or variant ATTR amyloidosis, represented as either hATTR or ATTRv) or the accumulation of non-mutated TTR protein (wild-type ATTR amyloidosis, or ATTRwt). The phenotypic presentation of ATTRv amyloidosis is clinically heterogeneous and can be predominantly neurologic, predominantly cardiac, or mixed phenotype, depending on the particular TTR variant and other factors. ATTRwt amyloidosis is the most common type of ATTR amyloidosis and most often presents as CM. Diagnosing ATTR-CM can be difficult due to low disease awareness, indeterminate family history, and the heterogeneity of clinical presentation that can overlap with more common diseases. Both ATTRv-CM and ATTRwt- CM are associated with markedly poor quality of life at the time of diagnosis and progressive deterioration when untreated, with patients frequently being hospitalized. Therefore, accurate and prompt diagnosis and treatment are key to improving clinical outcomes in patients with ATTR-CM. Crucially, the emergence of multiple disease-modifying therapies has transformed the therapeutic landscape, offering mortality and morbidity benefits that were previously unavailable.
In this symposium, ATTR experts will describe strategies for improving recognition of clinical clues for ATTR-CM and for making an earlier and accurate diagnosis. Evidence with disease-modifying therapies for ATTRCM will be presented including interpretations of recently completed clinical trials. Most effective use of HF medications in ATTR-CM patients will also be discussed. Two cases with panel discussions will be presented, 1) avoiding pitfalls and explaining best practices to overcome management challenges, and 2) successfully addressing the complexities of diagnosing
hereditary ATTR-CM and recognizing the importance of genetic testing not only for the index patient but also for identifying at-risk family members and initiating evidence-based interventions.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Identify suggestive findings for ATTR-CM Summarize the diagnostic evaluation for cardiac amyloidosis
  • Interpret the evidence for ATTR-CM disease-modifying therapies
  • Discuss strategies for the use of HF medications in patients diagnosed with ATTR-CM
  • Explain the importance of genetic testing in the diagnosis of ATTR-CM
  • Describe the challenges associated with the management of transthyretin amyloidosis

Target Audience:

This educational activity is intended for cardiovascular clinicians.

Accreditation and Credit Designation Statements

Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Educational Grant:

Voxmedia gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP and Ionis Pharmaceuticals.

Disclosure Information

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

Americans with Disabilities Act:

Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 454 Morris Avenue, Springfield, New Jersey 07081 USA; Phone: 973-467-0500.